About the Company
seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SEEL News
Seelos Therapeutics files for 3.4M shares secondary offering
Seelos Therapeutics (NASDAQ:SEEL) filed for resale by investors of up to ~3.4M shares. The ~3.4M shares are issuable upon exercise of outstanding warrants to purchase shares, issued by us to the ...
Why Seelos Therapeutics Shares Are Trading Lower By 10%; Here Are 20 Stocks Moving Premarket
Oncorus, Inc. (NASDAQ: ONCR) fell 10.4% to $0.1967 in pre-market trading after jumping 10% on Friday. Oncorus recently posted a narrower-than-expected quarterly loss. Seelos Therapeutics ...
Seelos Therapeutics Inc SEEL
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Seelos Therapeutics (SEEL) Price Target Increased by 60.00% to 4.08
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients ...
Seelos Therapeutics, Inc. (SEEL) stock forecast and price target
Find the latest Seelos Therapeutics, Inc. SEEL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Seelos Therapeutics files patent for treatment of neurodegenerative diseases using viral vectors encoding peptides
Discover Seelos Therapeutics' innovative patent for treating neurodegenerative diseases with viral vectors inhibiting a-synuclein aggregation. Learn more about their groundbreaking methods and ...
Seelos Therapeutics Inc SEEL
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Seelos Therapeutics, Inc. Common Stock (SEEL)
Nasdaq provides press releases highlighting valuable information sent out by companies. Here you can find the company’s latest financial figures, contact information, and source version of the ...
Seelos Therapeutics, Inc. Common Stock (SEEL)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
SEEL Seelos Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Seelos Therapeutics, Inc. (SEEL)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Loading the latest forecasts...